{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:19:23Z","timestamp":1769595563964,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1016\/s0959-8049(98)00277-9","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T12:15:57Z","timestamp":1027599357000},"page":"2021-2026","source":"Crossref","is-referenced-by-count":108,"title":["Markers of bone resorption in patients treated with pamidronate"],"prefix":"10.1016","volume":"34","author":[{"given":"A.","family":"Lipton","sequence":"first","affiliation":[]},{"given":"L.","family":"Demers","sequence":"additional","affiliation":[]},{"given":"E.","family":"Curley","sequence":"additional","affiliation":[]},{"given":"V.","family":"Chinchilli","sequence":"additional","affiliation":[]},{"given":"L.","family":"Gaydos","sequence":"additional","affiliation":[]},{"given":"G.","family":"Hortobagyi","sequence":"additional","affiliation":[]},{"given":"R.","family":"Theriault","sequence":"additional","affiliation":[]},{"given":"D.","family":"Clemens","sequence":"additional","affiliation":[]},{"given":"L.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"J.","family":"Seaman","sequence":"additional","affiliation":[]},{"given":"R.","family":"Knight","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0959-8049(98)00277-9_BIB1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/1097-0142(1950)3:1<74::AID-CNCR2820030111>3.0.CO;2-7","article-title":"Metastases in carcinoma. Analysis of 1,000 autopsied cases","volume":"3","author":"Abrams","year":"1950","journal-title":"Cancer"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00666208","article-title":"Osteolytic bone metastases in breast cancer","volume":"32","author":"Yoneda","year":"1994","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/263507a0","article-title":"Mechanisms of bone destruction in the development of skeletal metastases","volume":"263","author":"Galaski","year":"1976","journal-title":"Nature"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB4","doi-asserted-by":"crossref","unstructured":"Fujimoto D, Moriguchi T, Ishida T, et al. The structure of pyridinoline, a collagen cross-link. Biochem Biophys Res Commun 1978, 84, 52\u201357.","DOI":"10.1016\/0006-291X(78)90261-9"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB5","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1042\/bj2150167","article-title":"Cross-linking of collagen: isolation, structural characterization and glycosylation of pyridinoline","volume":"215","author":"Robins","year":"1983","journal-title":"Biochem J"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB6","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/0003-2697(84)90101-5","article-title":"Quantitation of hydroxypyridinium cross-links in collagen by high-performance liquid chromatography","volume":"137","author":"Eyre","year":"1984","journal-title":"Anal Biochem"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB7","doi-asserted-by":"crossref","unstructured":"Ogawa T, Ono T, Tsuda M, et al. A novel fluor in insoluble collagen: a cross-linking molecule in collagen molecule. Biochem Biophys Res Commun 1982, 107, 1252\u20131257.","DOI":"10.1016\/S0006-291X(82)80132-0"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB8","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0167-4838(87)90282-2","article-title":"Pyridinium cross-links of bone collagen and their location in peptides isolated from rat femur","volume":"914","author":"Robins","year":"1987","journal-title":"Biochem Biophys Acta"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB9","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0003-2697(88)90274-6","article-title":"Quantitative analysis of the pyridinium cross-links of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography","volume":"169","author":"Black","year":"1988","journal-title":"Anal Biochem"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB10","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF02556315","article-title":"Excretion of pyridinium cross-links of collagen in ovariectomized rats as urinary markers for increased bone resorption","volume":"44","author":"Black","year":"1989","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB11","doi-asserted-by":"crossref","unstructured":"Robins SP, Block D, Paterson CR, et al. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991, 21, 310\u2013315.","DOI":"10.1111\/j.1365-2362.1991.tb01375.x"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB12","doi-asserted-by":"crossref","unstructured":"Hanson DA, Weis MAE, Bollen AM, et al. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992, 7, 1251\u20131258.","DOI":"10.1002\/jbmr.5650071119"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB13","doi-asserted-by":"crossref","unstructured":"Lipton A, Demers L, Daniloff Y, et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 1993, 39, 614\u2013618.","DOI":"10.1093\/clinchem\/39.4.614"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB14","doi-asserted-by":"crossref","unstructured":"Demers L, Costa L, Chinchilli V, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995, 41, 1489\u20131494.","DOI":"10.1093\/clinchem\/41.10.1489"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB15","doi-asserted-by":"crossref","unstructured":"Body JJ, Borkowski A, Cleeren A, et al. Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate. J Clin Oncol 1986, 4, 1177\u20131183.","DOI":"10.1200\/JCO.1986.4.8.1177"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB16","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/bjc.1987.225","article-title":"(3 amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcemia of breast cancer","volume":"56","author":"Coleman","year":"1987","journal-title":"Br J Cancer"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB17","doi-asserted-by":"crossref","unstructured":"Morton AR, Cantrill JA, Craig AE, et al. Single dose versus daily intravenous aminohydroxypropylidene bisphosphonate (APD) for the hypercalcemia of malignancy. Br Med J 1988, 296, 811\u2013814.","DOI":"10.1136\/bmj.296.6625.811"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB18","unstructured":"Ralston SH, Alzaid AA, Gallacher SJ, et al. Clinical experience with aminohydroxypropylidene bisphosphonate (APD) in the management of cancer-associated hypercalcemia. Q J Med 1988, 69, 825\u2013834."},{"key":"10.1016\/S0959-8049(98)00277-9_BIB19","doi-asserted-by":"crossref","unstructured":"Thiebaud D, Jaeger P, Jacquet AF, et al. Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 1988, 6, 762\u2013768.","DOI":"10.1200\/JCO.1988.6.5.762"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB20","doi-asserted-by":"crossref","unstructured":"Nussbaum S, Younger J, Vandepol CJ, et al. Single dose intravenous therapy with pamidronate (APD) for the treatment of hypercalcemia of malignancy: comparison of 30, 60, and 90mg dosages. Am J Med 1993, 95, 297\u2013304.","DOI":"10.1016\/0002-9343(93)90282-T"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB21","doi-asserted-by":"crossref","unstructured":"van Holten-Verzantvoort AT, Bijvoet OLM, Hermans J, et al. Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 1987, ii, 983\u2013985.","DOI":"10.1016\/S0140-6736(87)92555-4"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB22","doi-asserted-by":"crossref","unstructured":"Coleman RE, Woll PJ, Miles M, et al. Treatment of bone metastases from breast cancer with (3-amino-1-hydroxypropylidene)-1,1bisphosphonate (APD). Br J Cancer 1988, 56, 465\u2013469.","DOI":"10.1038\/bjc.1987.225"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB23","doi-asserted-by":"crossref","unstructured":"Morton AR, Cantrill JA, Pillai GV, et al. Sclerosis of lytic bone metastases after disodium aminohydroxypropylidene bisphosphonate (APD) in patients with breast carcinoma. Br Med J 1988, 297, 772\u2013773.","DOI":"10.1136\/bmj.297.6651.772"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB24","doi-asserted-by":"crossref","unstructured":"Adami S, Salvagno G, Guarrera G, et al. Dichloromethylene-diphosphonate in patients with prostate carcinoma metastatic to the skeleton. J Urol 1985, 134, 1152\u20131154.","DOI":"10.1016\/S0022-5347(17)47663-4"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB25","doi-asserted-by":"crossref","unstructured":"Glover D, Lipton A, Keller A, et al. Intravenous pamidronate disodium treatment of bone metastases in breast cancer. A dose-seeking study. Cancer 1994, 74, 2949\u20132955.","DOI":"10.1002\/1097-0142(19941201)74:11<2949::AID-CNCR2820741110>3.0.CO;2-Q"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB26","doi-asserted-by":"crossref","unstructured":"Berenson J, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal-related events in patients with advanced multiple myeloma. New Engl J Med 1996, 334, 488\u2013493.","DOI":"10.1056\/NEJM199602223340802"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB27","doi-asserted-by":"crossref","unstructured":"Hortobagyi G, Theriault R, Porter L, et al. Efficacy of pamidronate in reducing skeletal-related events in patients with breast cancer and lytic bone lesions. N Engl J Med 1996, 335, 1785\u20131791.","DOI":"10.1056\/NEJM199612123352401"},{"key":"10.1016\/S0959-8049(98)00277-9_BIB28","unstructured":"Lipton A, Theriault R, Leff R, et al. Long-term reduction of skeletal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy (in press)."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804998002779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804998002779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T16:19:01Z","timestamp":1620231541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804998002779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":28,"journal-issue":{"issue":"13","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["S0959804998002779"],"URL":"https:\/\/doi.org\/10.1016\/s0959-8049(98)00277-9","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}